It is widely recognized that immune effector cells expressing PD-1 migrate from the blood to the sites of immune priming in secondary lymphoid organs or tumor microenvironment via CXCR5/CXCL13, in which they become resident cells (58). Here, PDCD1 is linked to neoplasm.